期刊
NATURE REVIEWS UROLOGY
卷 9, 期 7, 页码 386-396出版社
NATURE PORTFOLIO
DOI: 10.1038/nrurol.2012.117
关键词
-
资金
- National Cancer Institute Specialized Program of Research Excellence
- Bernard L. Schwartz Scholar Award by the Patrick C. Walsh Cancer Research Fund
- Patana Fund of the Brady Urological Institute
Cancer/testis antigens (CTAs) are a group of tumour-associated antigens (TAAs) that display normal expression in the adult testis-an immune-privileged organ-but aberrant expression in several types of cancers, particularly in advanced cancers with stem cell-like characteristics. There has been an explosion in CTA-based research since CTAs were first identified in 1991 and MAGE-1 was shown to elicit an autologous cytotoxic T-lymphocyte (CTL) response in a patient with melanoma. The resulting data have not only highlighted a role for CTAs in tumorigenesis, but have also underscored the translational potential of these antigens for detecting and treating many types of cancers. Studies that have investigated the use of CTAs for the clinical management of urological malignancies indicate that these TAAs have potential roles as novel biomarkers, with increased specificity and sensitivity compared to those currently used in the clinic, and therapeutic targets for cancer immunotherapy. Increasing evidence supports the utilization of these promising tools for urological indications.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据